UCB Moves Up Myasthenia Gravis Pipeline With Rozanolixizumab Win

Slips Into Second Place Behind Argenx's Efgartigimod

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.